Head-to-head dispatch
PepHaūs vs Peter MD
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
PepHaūs is a telehealth pharmacy offering compounded GLP-1 weight-loss treatment — semaglutide from $152/mo and tirzepatide from $246/mo — prescribed by U.S.-licensed providers and shipped from 503A…
Marked down on: Compounding pharmacy partners aren't named on the marketing site
Desk Score
A physician-prescribed telehealth brand pairing GLP-1 tirzepatide and compounded semaglutide+B12 with TRT, sermorelin, NAD+, hair-loss and ED care on one account — tirzepatide from $249/mo, semaglutide+B12 from $149/mo.
Marked down on: Tirzepatide steps up after month one — $149 for the first month, then $249/mo billed quarterly
Peter MD takes this head-to-head with the higher Desk Score, 80/100 (B−) against 77/100 (C+) for PepHaūs. PepHaūs still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
PepHaūs
77/100
C+
Peter MD
80/100
B−
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | PepHaūs | Peter MD |
|---|---|---|
| Semaglutide | $152/mo (quarterly plan, compounded) | $149/mo (GLP1+B12, compounded, first-time tier; $139/mo returning-patient tier) |
| Tirzepatide | $246/mo (compounded) | $249/mo (60mg, billed quarterly; $149 first month) |
| Coverage | All 50 states | Most states (restrictions vary by treatment — excludes several, incl. AL, ID) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Shoppers who want all-inclusive compounded GLP-1 pricing shipped nationwide. | Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes. |
| Desk Score | 77/100C+ | 80/100B− |
The verdict
Desk pick — Peter MDPeter MD takes this head-to-head with the higher Desk Score, 80/100 (B−) against 77/100 (C+) for PepHaūs. PepHaūs still holds its ground where its strengths line up with yours.
Choose PepHaūs if…
Shoppers who want all-inclusive compounded GLP-1 pricing shipped nationwide.
$152/mo (quarterly plan, compounded) sema · $246/mo (compounded) tirz · All 50 states
Choose Peter MD if…
Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes.
$149/mo (GLP1+B12, compounded, first-time tier; $139/mo returning-patient tier) sema · $249/mo (60mg, billed quarterly; $149 first month) tirz · Most states (restrictions vary by treatment — excludes several, incl. AL, ID)
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: PepHaūs · Peter MD.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- PepHaūs vs CoreAge Rx
- Peter MD vs Vaylen
- PepHaūs vs Strut Health
- Peter MD vs Ondra Health
- PepHaūs vs Invigor Medical
- Peter MD vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.